Detection of Esophageal Cancer by Assay of Novel Methylated DNA Markers in Plasma

Overview

About this study

The purpose of the study is to see if the plasma assay of MDMs using optimized markers and analytically sensitive assays will detect early-stage esophageal cancer at high specificity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Study Criteria:

Exclusions:

  • Age < 18
  • Primary cancer outside of the esophagus within the last 5 years (not including basal or squamous cell skin cares)
  • History of Esophageal cancer
  • Intervention to completely remove the current target pathology
  • Any endoscopic treatment to current target pathology [Endoscopic intervention examples: Photodynamic therapy, Halo, Cryotherapy, Multi-polar coagulation]
  • Prior chemotherapy class drugs or radiation for the primary esophageal cancer prior to blood or stool collection
  • Biopsy (excluding skin) and/or brushing 3 days prior to blood collection  
  • IV contrast given within 24 hours of blood collection

 

Additional Stool Exclusions:

  • Bowel prep <7 days prior to stool collection
  • Oral contrast given within 7 days of stool collection
  • Removal of more than 50% of colon or presence of ileostomy
  • Enteral feeds or TPN
  • Diagnosis of inflammatory bowel disease
  • If patient has had colonoscopy within 5 years, were pre-cancerous polyps (>1cm or villous)
  • Enteric barium studies within the prior 7 days of stool collection

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Kisiel, M.D.

Open for enrollment

Contact information:

Kari Lowrie

(507)266-3778

Lowrie.Kari@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20439038

Mayo Clinic Footer